|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0003316,
umls-concept:C0039195,
umls-concept:C0042196,
umls-concept:C0205210,
umls-concept:C0522503,
umls-concept:C0694898,
umls-concept:C0871261,
umls-concept:C1704632,
umls-concept:C1706817,
umls-concept:C1707520,
umls-concept:C2911692
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
2010-7-23
|
|
pubmed:abstractText |
Clinical studies of WT1-targeted cancer vaccine are being performed. However, WT1-specific Th response in cancer patients remains unclear. Using quantitative real-time RT-PCR, we investigated IFN-gamma and IL-10 mRNA expression from Th cells by stimulation with helper peptide WT1(332). Seventeen patients, of whom 10 had achieved stable disease and the remaining 7 had progressive disease, were weekly vaccinated with WT1 CTL epitope (modified WT1(235)) and examined for WT1(332)-specific Th response. A clear correlation between WT1(332)-specific Th response and clinical response was observed at 4 weeks post-vaccination. In patients who responded, a clear inverse correlation between IL-10-type and IFN-gamma-type WT1(332)-specific Th response was detected at pre- and 4 weeks post-vaccination, and the shift of the Th response from IL-10-type dominancy at early phase to IFN-gamma-type dominancy at late phase was observed. From this study we concluded that occurrence of WT1(332)-specific Th response could predict good clinical response of WT1 CTL epitope vaccination.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
1791-7530
|
|
pubmed:author |
pubmed-author:FujikiFumihiroF,
pubmed-author:HashimotoNaoyaN,
pubmed-author:HosenNaokiN,
pubmed-author:ItoToshinoriT,
pubmed-author:IzumotoShuichiS,
pubmed-author:KawakatsuMaiM,
pubmed-author:KawaseIchiroI,
pubmed-author:MarunoMotohikoM,
pubmed-author:MyouiAkiraA,
pubmed-author:NakajimaHirokoH,
pubmed-author:NishidaSumiyukiS,
pubmed-author:NoguchiShinzaburoS,
pubmed-author:NonomuraNorioN,
pubmed-author:OjiYusukeY,
pubmed-author:OkaYoshihiroY,
pubmed-author:OkuyamaAkihikoA,
pubmed-author:ShirakataToshiakiT,
pubmed-author:SugiyamaHaruoH,
pubmed-author:TaguchiTetsuyaT,
pubmed-author:TakedaYutakaY,
pubmed-author:Tanaka-HaradaYukieY,
pubmed-author:TatsumiNaoyaN,
pubmed-author:TsuboiAkihiroA,
pubmed-author:UedaSatsukiS,
pubmed-author:YoshimineToshikiT
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
30
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2247-54
|
|
pubmed:meshHeading |
pubmed-meshheading:20651376-Adult,
pubmed-meshheading:20651376-Aged,
pubmed-meshheading:20651376-Cancer Vaccines,
pubmed-meshheading:20651376-Epitopes, T-Lymphocyte,
pubmed-meshheading:20651376-Female,
pubmed-meshheading:20651376-Humans,
pubmed-meshheading:20651376-Interferon-gamma,
pubmed-meshheading:20651376-Interleukin-10,
pubmed-meshheading:20651376-Male,
pubmed-meshheading:20651376-Middle Aged,
pubmed-meshheading:20651376-RNA, Messenger,
pubmed-meshheading:20651376-T-Lymphocytes, Cytotoxic,
pubmed-meshheading:20651376-T-Lymphocytes, Helper-Inducer,
pubmed-meshheading:20651376-Vaccination,
pubmed-meshheading:20651376-WT1 Proteins
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
A clear correlation between WT1-specific Th response and clinical response in WT1 CTL epitope vaccination.
|
|
pubmed:affiliation |
Department of Functional Diagnostic Science, Osaka University Graduate School of Medicine, 1-7, Yamada-Oka, Suita City, Osaka 565-0871, Japan.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
